Covid-19

  • You are viewing Orangepower as a Guest. To start new threads, reply to posts, or participate in polls or contests - you must register. Registration is free and easy. Click Here to register.

Rack

Legendary Cowboy
Oct 13, 2004
21,513
9,539
1,743
Earth
@rx- the wife just told me that baby fawns are left by their mothers in a safe place and they will come get them so to leave it alone. Baby fawns don’t have a scent according to an article she read on the net. So they are safe. Anyway cool pic and the beagles from yesterday are outstanding. I have a beagle, or she has me anyway.

Btw, Im live from radio free Oklahoma broadcasting from an undisclosed location in occupied New Mexico.
 

RxCowboy

Has no Rx for his orange obsession.
A/V Subscriber
Nov 8, 2004
75,477
52,528
1,743
Wishing I was in Stillwater
@rx- the wife just told me that baby fawns are left by their mothers in a safe place and they will come get them so to leave it alone. Baby fawns don’t have a scent according to an article she read on the net. So they are safe. Anyway cool pic and the beagles from yesterday are outstanding. I have a beagle, or she has me anyway.

Btw, Im live from radio free Oklahoma broadcasting from an undisclosed location in occupied New Mexico.
There's another pic, mama is about 50 yards away watching carefully. My nephew was careful not to touch it, just wanted to be close enough to observe for a few minutes. Here's the pic with mama.
1590395881846.png
 

RxCowboy

Has no Rx for his orange obsession.
A/V Subscriber
Nov 8, 2004
75,477
52,528
1,743
Wishing I was in Stillwater
Me too. It would make sense.

Sent from my Moto Z (2) using Tapatalk
Well, I'm not sure it makes sense, and that's why I said I hope it's true. If asymptomatic people aren't shredding much virus and aren't contagious, then who are they getting it from? I think it's safe to assume they haven't all been exposed to patients on vents. It is most likely they are getting it from each other. So, if I had to make a guess, we'll have a later study that shows this one to be untrue.
 

RxCowboy

Has no Rx for his orange obsession.
A/V Subscriber
Nov 8, 2004
75,477
52,528
1,743
Wishing I was in Stillwater
Me too. It would make sense.

Sent from my Moto Z (2) using Tapatalk
Some observations from the study:

"Case A and her brother both denied visiting Wuhan (the epidemic area in China) and any contact with COVID-19 patients. They wore masks all the time except at meals and drinking. How she became infected was unknown."

The mask did not keep her from getting COVID-19. But then how she became infected was unknown.

"The statistics of 35 patients are displayed in Table 2 . All patients also wore masks except for eating or drinking and were admitted to infectious department for medical isolation."

They put masks on the patients when they admitted them.

"In total, 196 family members were enrolled. The situation on wearing masks was the same as that in patients. Local CDC took charge of following up 172 among them, who were ruled out SARS-CoV-2 infection after 14-days medical isolation, as far as we know. The rest of the escorts were placed in designated locations by GCDC for quarantine. Of these 24 escorts, 11 were male and 13 were female. They aged from 24 to 86 years old and the median age was 47.5 years old (interquartile range, 34.0 to 57.0). The median contact time was five days (interquartile range, 1.0 to 11.0). Regarding examinations, at least two nucleic acid tests were negative. All the attendants except a family member had no respiratory symptoms in the time of quarantine. Details as below."

They used masks to prevent the spread among close contacts.

"To ensure safety, 224 hospital staffs who had come into contact with Case A were screened. As is clearly shown in Table 3 , their identities were mainly composed of doctors (59 [26.3%]) and nurses (101 [45.1%]). Others coexisted in the same room with Case A for work, such as security guards, cleaners, transportation personnel, etc. Of these 224 staffs, 103 were male and 121 were female, with ages ranging 21–60 years old. The median age was 35 years old (interquartile range, 28.0 to 42.0). Most of them were emergency workers so that they had long exposure to confirmed case. Oppositely, some doctors in other departments had a brief stay, approximately one to 2 h, because of emergency consultation. It is noteworthy that all personnel working in ED must take medical protection – namely, using N95 mask, putting on isolation gown and wearing goggle."

The hospital staff used PPE.

"No respiratory symptoms were observed, either existing or emerging."

The masks on patients and PPE on providers worked.

This study actually says nothing about the R0 of asymptomatic patients. It says a LOT about mitigation procedures.
 

wrenhal

Federal Marshal
Aug 11, 2011
10,063
4,287
743
Me too. It would make sense.

Sent from my Moto Z (2) using Tapatalk
Well, I'm not sure it makes sense, and that's why I said I hope it's true. If asymptomatic people aren't shredding much virus and aren't contagious, then who are they getting it from? I think it's safe to assume they haven't all been exposed to patients on vents. It is most likely they are getting it from each other. So, if I had to make a guess, we'll have a later study that shows this one to be untrue.
I would think they are somehow being exposed to someone with mild symptoms initially, rather than another asymptomatic person. Without an even mild fever, how are you contagious. Your body isn't doing any fighting apparently.

Sent from my Moto Z (2) using Tapatalk
 

RxCowboy

Has no Rx for his orange obsession.
A/V Subscriber
Nov 8, 2004
75,477
52,528
1,743
Wishing I was in Stillwater
I would think they are somehow being exposed to someone with mild symptoms initially, rather than another asymptomatic person. Without an even mild fever, how are you contagious. Your body isn't doing any fighting apparently.

Sent from my Moto Z (2) using Tapatalk
It's something that the study can't explain.
 

RxCowboy

Has no Rx for his orange obsession.
A/V Subscriber
Nov 8, 2004
75,477
52,528
1,743
Wishing I was in Stillwater
From https://www.contagionlive.com/news/who-hydroxychloroquine-treatment-covid-19-solidarity-trial

WHO Suspends Hydroxychloroquine Treatment in COVID-19 Solidarity Trial
MAY 25, 2020 | KEVIN KUNZMANN

The World Health Organization (WHO) has announced intentions to temporarily suspend the hydroxychloroquine arm of its Solidarity Trial while the trial’s executive group reviews available, robust randomized data assessing the polarizing therapy in treatment of patients with confirmed coronavirus 2019 (COVID-19).

In an announcement made by WHO Director-General Dr. Tedros Adhanom Ghebreyesus on Monday afternoon, the global organization cited data published by The Lancet on Friday, May 22, which showed autoimmune therapies hydroxychloroquine or chloroquine—with or without a macrolide—did not conclusively show in-hospital outcome benefits.

The trial
A team of investigators from the US and Switzerland, led by Mandeep R. Mehra, MD, of Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, conducted the international registry analysis of the considered therapies among 96,032 SARS-CoV-2 confirmed patients hospitalized in 671 hospitals across 6 continents.

The patient population was split among 14,888 (15.5%) patients receiving treatment—1868 on chloroquine, 3783 on chloroquine plus macrolide, 3016 on hydroxychloroquine, and 6221 on hydroxychloroquine plus macrolide—and 81,144 serving as control, meaning they received none of these treatments.

Mehra and colleagues excluded data from patients for whom one of the observed therapies was initiated >48 hours post-coronavirus diagnosis or while they were on mechanical ventilation, as well as those who received remdesivir. They sought an outcome of in-hospital mortality and de-novo ventricular arrhythmias.

Combination hydroxychloroquine and second-generation macrolides including azithromycin have been advocated for COVID-19 care by public officials, investigators noted, despite their limited evidence for efficacy—and even previous research showing any combination of the therapies can increase cardiovascular event risk, including ventricular tachycardia or ventricular fibrillation.

Despite this conflict between public advocacy and clinical concern, countries have opted to stockpile the drugs in question over the past few months.

“Although several multicenter randomized controlled trials are underway, there is a pressing need to provide accurate clinical guidance because the use of chloroquine or hydroxychloroquine along with macrolides is widespread, often with little regard for potential risk,” investigators wrote.

Mean patient age was 53.8 years, with 46.3% of observed patients being women. With control for confounding factors including age, sex, race/ethnicity, body mass index (BMI), cardiometabolic disease history, immunosuppressed condition, lung disease, and smoking status, every combination of chloroquine, hydroxychloroquine, and a macrolide therapy was associated with an increased risk of in-hospital mortality versus other COVID-19 therapies:
  • Hydroxychloroquine: 18.0% (hazard ratio [HR], 1.335; 95% CI, 1.2231.457)
  • Hydroxychloroquine plus macrolide: 23.8% (HR, 1.447; 95% CI, 1.4471.368)
  • Chloroquine: 16.4% (HR, 1.365; 95% CI, 1.2181.531)
  • Chloroquine plus macrolide: 22.2% (HR, 1.368; 95% CI, 1.2731.469)
  • Control: 9.3%
  • Risk of patient de-novo ventricular arrhythmia during hospitalization was, again, significantly increased with every combination of observed therapy versus control:
  • Hydroxychloroquine: 6.1% (HR, 2.369; 95% CI, 1.9352.900)
  • Hydroxychloroquine plus macrolide: 8.1% (HR, 5.106; 95% CI, 4.1065.983)
  • Chloroquine: 4.3% (HR, 3.561; 95% CI, 1.9352.900)
  • Chloroquine plus macrolide: 6.5% (HR, .4011; 95% CI, 3.3444.812)
  • Control: 0.3%
The findings, which were comprised of 63,315 (65.9%) COVID-19 patients in North America, also indicated that greater patient BMI is associated with worse in-hospital survival rates. They also implied that drugs designed to stabilize cardiovascular function, including and improve endothelial cell dysfunction, including ACE inhibitors, might improve COVID-19 patient prognosis.

But overall, the associated risk of in-hospital mortality and cardiovascular events in patients treated with chloroquine, hydroxychloroquine, and/or a macrolide led to a severe recommendation from Mehra and colleagues.

“These findings suggest that these drug regimens should not be used outside of clinical trials and urgent confirmation from randomized clinical trials is needed,” they concluded.

Solidarity Trial
According to the WHO’s website, the Solidarity Trial is an ongoing, actively-recruiting assessment which currently includes 3500 patients from 17 countries. However, recruitment is being pursued in twice that many countries (35), including 400 hospitals.

The international clinical trial is assisting clinicians in finding effective treatments for COVID-19, comparing 4 therapy options to standard of care for their relative effectiveness against the virus.

Executive investigators are aiming to uncover slowed disease progression or improved survival associated with any of the currently observed drugs—or any new candidates added based on emerging evidence.

“The pressure COVID-19 puts on health systems means that WHO considered the need for speed and scale in the trial,” the WHO’s site reads. “While randomized clinical trials normally take years to design and conduct, the Solidarity Trial will reduce the time taken by 80%.”

WHO response
In Adhoman’s media briefing on May 25, he shared that the Solidarity Trial executive group met on the day following the published Lancet findings.

This group, which represents 10 of the countries participating in the global COVID-19 therapy trial, agreed that a comprehensive analysis and critical appraisal of this hydroxychloroquine evidence, and other data, was necessary.

“The review will consider data collected so far in the Solidarity Trial and in particular robust randomized available data, to adequately evaluate the potential benefits and harms from this drug,” Adhoman stated.

The director-general reiterated that this concern relates directly to the use of hydroxychloroquine and chloroquine in COVID-19 treatment, and that other arms of the Solidarity Trial are continuing.

Use of the therapies in question for autoimmune disease or malaria care, Adhoman continued, is still accepted as generally safe by the WHO. Further updates on the organization’s assessment of hydroxychloroquine and chloroquine can be expected at a later date.
 

Rack

Legendary Cowboy
Oct 13, 2004
21,513
9,539
1,743
Earth
Lol, you might compare population density IF you were honest. Or even consider ports of entry into the country IF you were honest. But.....
It's true that the majority of those areas are "dense" to continue to elect the officials they do. Let's hope this incident changes that. :innocent:
 
Last edited:

NotOnTV

BRB -- Taking an okie leak
Sep 14, 2010
9,574
6,862
1,743
Gondor
The fact that the reopen vs. cower in fear crowds are drawn largely on party lines should tell you all you need to know -- the left wants the economy to stay depressed through the November election.